Keyphrases
Improved Outcomes
100%
Childrens
100%
Oncology
100%
Minimal Residual Disease
100%
Myeloid Leukemia of Down Syndrome
100%
Daunorubicin
60%
Ara-C
60%
Event-free Survival
60%
High Dose
40%
Overall Survival
40%
5-year Survival
40%
Clinical Trials
20%
Risk Stratification
20%
Group Studies
20%
Cytarabine
20%
Treatment Outcome
20%
Prognostic Factors
20%
Relapsed or Refractory Acute Myeloid Leukemia
20%
Clinical Significance
20%
Drug Dosing
20%
Early Use
20%
Flow Cytometry
20%
Blast Cells
20%
4-cycle
20%
Treatment-related Mortality
20%
Treatment-related Morbidity
20%
Reduced Toxicity
20%
Treatment Schema
20%
Intensified Therapy
20%
2-cycles
20%
Relapsed or Refractory
20%
Impact Outcomes
20%
Disease Levels
20%
Medicine and Dentistry
Oncology
100%
Myeloid Leukemia
100%
Down Syndrome
100%
Minimal Residual Disease
100%
Liposomal Daunorubicin
60%
Overall Survival
60%
Event Free Survival
60%
Drug Megadose
40%
Ex Vivo
20%
Clinical Trial
20%
Cytarabine
20%
Risk Stratification
20%
Prognostic Factor
20%
Clinical Significance
20%
Flow Cytometry
20%
Blast Cell
20%
Disease Free Survival
20%
Leukemia
20%
Treatment Outcome
20%